MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation
This study has been completed.
Sponsor:
InSightec
Information provided by:
InSightec
ClinicalTrials.gov Identifier:
NCT00295217
First received: February 21, 2006
Last updated: January 13, 2009
Last verified: January 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this study is to validate the new ExAblate Application software V4.2 by developing additional data that shows the safety of this treatment. The ExAblate is intended to ablate uterine fibroid tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure. Patients must have a uterine size of less than 24 weeks and not seeking treatment for reasons of improving fertility.
| Condition | Intervention | Phase |
|---|---|---|
|
Uterine Fibroids Uterine Leiomyomas |
Device: ExAblate 2000 |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device |
Further study details as provided by InSightec:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Women who present with symptomatic uterine fibroids and are not seeking treatment for the reason of improving fertility.
- Able and willing to give consent and able to attend all study visits.
- Patient is pre or peri-menopausal (within 12 months of last menstrual period).
- Able to communicate sensations during the ExAblate procedure.
- Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone).
- Fibroids(s) clearly visible on non-contrast MRI.
Exclusion Criteria:
- Metallic implants that are incompatible with MRI
- Sensitive to MRI contrast agents
- Severe claustrophobia that would prevent completion of procedure in MR unit
- Who are pregnant or desire to become pregnant in the future. Pregnancies following ExAblate treatment could be dangerous for both mother and fetus.
- Pedunculated fibroids
- Active pelvic inflammatory disease (PID)
- Active local or systemic infection
- Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia
- Intrauterine device (IUD) anywhere in the treatment path
- Dermoid cyst of the ovary anywhere in the treatment path
- Extensive abdominal scarring that cannot be avoided by redirection of the beam (e.g., due to Caesarean section or repeated abdominal surgeries)
- Undiagnosed vaginal bleeding
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00295217
Locations
| United States, California | |
| University of California at San Diego | |
| LaJolla, California, United States, 92037 | |
| United States, Massachusetts | |
| Lahey Clinic | |
| Burlington, Massachusetts, United States, 01805 | |
| United States, Michigan | |
| KNI | |
| Kalamazoo, Michigan, United States, 49048 | |
| United States, New York | |
| Cornell Vascular | |
| New York, New York, United States, 10022 | |
Sponsors and Collaborators
InSightec
Investigators
| Principal Investigator: | George Holland, M.D. | Lahey Clinic |
| Principal Investigator: | Mark Shaman, M.D. | KNI |
| Principal Investigator: | Robert Min, M.D. | Cornell |
| Principal Investigator: | Anne Roberts, M.D. | University of California, San Diego |
More Information
Additional Information:
Sponsor web page 
No publications provided
| ClinicalTrials.gov Identifier: | NCT00295217 History of Changes |
| Other Study ID Numbers: | UF017, Continued Access |
| Study First Received: | February 21, 2006 |
| Last Updated: | January 13, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by InSightec:
|
Fibroids Uterine Leiomyomas ExAblate MrgFUS |
Additional relevant MeSH terms:
|
Leiomyoma Myofibroma Neoplasms, Muscle Tissue Neoplasms, Connective and Soft Tissue |
Neoplasms by Histologic Type Neoplasms Neoplasms, Connective Tissue Connective Tissue Diseases |
ClinicalTrials.gov processed this record on May 16, 2013